Nanomedicine contributes to cancer therapeutics in several ways, harnessing some of the remarkable properties of nanomaterials to target tumor cells with increasing specificity. Nano-scale therapeutic strategies enable the simultaneous transport of hydrophilic and hydrophobic drugs across physical and physiological barriers like the blood-brain barrier. Alternative routes of drug administration, such as the intranasal route, have become viable, with more promising therapies for highly lethal tumors like glioblastomas. Cancer nanomedicine allows increased solubility and bioavailability of anti-cancer drugs, reducing their toxicity.
Multi-drug delivery systems such as dendrimers, noble metal nanoparticle drug delivery systems, nanoparticle-based theranostics, and nano-biomarkers may well bring about a sea change in cancer therapeutics. This review presents an overview of the scope of cancer nanomedicine, including immunotherapy for cancer.
S. Tinkle, S.E. McNeil, S. Mühlebach, R. Bawa, G. Borchard, Y. Barenholz, L. Tamarkin and N. Desai, “Nanomedicines: addressing the scientific and regulatory gap,” Annals of the New York Academy of Sciences, vol. 1313, pp. 35-56, April 2014, https://doi.org/10.1111/nyas.12403.
D. Gao, X. Guo, X. Zhang, S. Chen, Y. Wang, T. Chen, G. Huang, Y. Gao, Z. Tian and Z. Yang, “Multifunctional phototheranostic nanomedicine for cancer imaging and treatment,” Materials Today Bio, vol. 5, no. 100035, pp. 1-33, January 2020, https://doi.org/10.1016/j.mtbio.2019.100035.
Jeevanandam, J, Barhoum, A, Chan, YS, Dufresne, A, and Danquah, MK 2018, “Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations,” Beilstein Journal of Nanotechnology, vol. 9, pp. 1050-1074, April 2018, https://doi.org/10.3762/bjnano.9.98.
M. Rahm, R. Hoffmann and N.W. Ashcroft, “Atomic and ionic radii of elements 1–96,” Chemistry: A European Journal, vol. 22, no. 41, pp. 14625-14632, August 2016.
J. Szebeni and Y.C. Barenholz, “Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes,” in Handbook of harnessing biomaterials in nanomedicine – preparation, toxicity and applications, D. Peer, Ed. Singapore: Pan Stanford, 2012, ch. 11, pp. 309-335.
D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751-760, December 2007.
R.D. Toothaker and P.G. Welling, “The Effect of Food on Drug Bioavailability,” Annual Review of Pharmacology and Toxicology, vol. 20, no. 9, pp. 173-199, February 1980, https://doi.org/10.1146/annurev.pa.20.040180.001133.
V.B. Junyaprasert, and B. Morakul, “Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs,” Asian Journal of Pharmaceutical Sciences, vol. 10, no. 1, pp. 13-23, August 2014, https://doi.org/10.1016/j.ajps.2014.08.005.
S. Kalepu and V. Nekkanti, “Insoluble drug delivery strategies: review of recent advances and business prospects,” Acta Pharmaceutica Sinica B, vol. 5, no. 5, pp. 442-453, September 2015, https://doi.org/10.1016/j.apsb.2015.07.003.
S. Dizaj, Z. Vazifehasl, S. Salatin, K. Adibkia, and Y. Javadzadeh, “Nanosizing of drugs: effect on dissolution rate,” Research in Pharmaceutical Sciences, vol. 10, pp. 95-108, Apr 2015.
N. Hoshyar, S. Gray, H. Han, and G. Bao, “The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction,” Nanomedicine (London), vol. 6, pp. 673-692, March 2016, https://doi.org/10.2217/nnm.16.5.
R.N. Pawar S.N. Chavan, and M.D. Menon, “Development, characterization, and evaluation of tinidazole nanosuspension for treatment of amoebiasis,” Journal of Nanomedicine and Nanotechnology, vol. 7, no. 6, pp. 1-4, January 2016, https://doi.org/10.4172/2157-7439.1000413.
R. Toy, P.M. Peiris, K.B. Ghaghada, and E. Karathanasis, “Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles,” Nanomedicine (London, England), vol. 9, no. 1, pp. 121-134, January 2014, https://doi.org/10.2217/nnm.13.191.
C.A. Vaine, M.K. Patel, J. Zhu, E. Lee, R.W. Finberg, R.C. Hayward, and E.A. Kurt-Jones, “Tuning innate immune activation by surface texturing of polymer microparticles: the role of shape in inflammasome activation,” The Journal of Immunology, vol. 190, no. 7, pp. 3525-3532, February 2013, https://doi.org/10.4049/jimmunol.1200492.
P.L. Rodriguez, T. Harada, D. Christian, D.A. Pantano, R.K. Tsai, and D.E. Discher, “Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles,” Science, vol. 339, no. 6122, pp. 971-975, February 2013, https://doi.org/10.1126/science.1229568.
F.A. Bruinsmann, G.R. Vaz, A. de C.S. Alves, T. Aguirre, A.R. Pohlmann, S.S. Guterres, and F. Sonvico, “Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials,” Molecules, vol. 24, no. 23, pp. 1-32, November 2019, https://doi.org/10.3390/molecules24234312.
C. Comfort, G. Garrastazu, M. Pozzoli, and F. Sonvico, “Opportunities and challenges for the nasal administration of nanoemulsions,” Current Topics in Medicinal Chemistry, vol. 15, no. 4, pp. 356-368, January 2015, https://doi.org/10.2174/1568026615666150108144655.
L. Chu, A. Wang, L. Ni, X. Yan, Y. Song, M. Zhao, K. Sun, H. Mu, S. Liu, Z. Wu, and C. Zhang, “Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting,” Drug Delivery, vol. 25, no. 1, pp. 1634-1641, September 2018, https://doi.org/10.1080/10717544.2018.1494226.
D. Lombardo, M.A. Kiselev, and M.T. Caccamo, “Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine,” Journal of Nanomaterials, vol. 2019, no. 3702518, pp. 1-26, February 2019, https://doi.org/10.1155/2019/3702518.
A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran, SW. Joo, N. Zarghami, Y. Hanifehpour, M. Samiei, M. Kouhi, and K. Nejati-Koshki, “Liposome: classification, preparation, and applications,” Nanoscale Research Letters, vol. 8, no. 1, p. 102, February 2013, https://doi.org/10.1186/1556-276X-8-102.
L. Dutta, B. Mukherjee, T. Chakraborty, M.K. Das, L. Mondal, S. Bhattacharya, R.H. Gaonkar, and M.C. Debnath, “Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain,” Drug Delivery, vol. 25, no. 1, pp. 504-516, February 2018, https://doi.org/10.1080/10717544.2018.1435749.
G. Bozzuto, and A. Molinari, “Liposomes as nanomedical devices,” International Journal of Nanomedicine, vol. 10, pp. 975-999, February 2015, https://doi.org/10.2147/IJN.S68861.
P.J.J. Francis, K.J. Arun, A.A. Navas, and I. Joseph, “Biomedical applications of polymers - an overview,” Current Trends in Engineering and Biosciences, vol. 15, no. 2, pp. 44-45, June 2018, https://doi.org/10.19080/ctbeb.2018.15.555909.
J. Karlsson, H.J. Vaughan, and J.J. Green, “Biodegradable polymeric nanoparticles for therapeutic cancer treatments,” Annual Review of Chemical and Biological Engineering, vol. 7, no. 9, pp. 105-127, June 2018, https://doi.org/10.1146/annurev-chembioeng-060817-084055.
P. Anitha, J. Bhargavi, G. Sravani, B. Aruna, and S. Ramkanth, “Recent progress of dendrimers in drug delivery for cancer therapy,” International Journal of Applied Pharmaceutics, vol. 10, pp. 34-42, September 2018, https://doi.org/10.22159/IJAP.2018V10I5.27075.
A.C.V. Doughty, A.R. Hoover, E. Layton, C.K. Murray, E.W. Howard, and W.R. Chen, “Nanomaterial applications in photothermal therapy for cancer,” Materials (Basel), vol. 12, no. 1, p. 779, March 2019, https://doi.org/10.3390/ma12050779.
C. Zhang, W. Bu, D. Ni, C. Zuo, C. Cheng, Q. Li, L. Zhang, Z. Wang, and J. Shi, “A polyoxometalate cluster paradigm with self-adaptive electronic structure for acidity/reducibility-specific photothermal conversion,” Journal of the American Chemical Society, vol. 138, no. 26, pp. 8156-8164, June 2016, https://doi.org/10.1021/jacs.6b03375.
F.M. Kouri, L.A. Hurley, W.L. Daniel, E.S. Day, Y. Hua, L. Hao, C.Y. Peng, T.J. Merkel, M.A. Queisser, C. Ritner, H. Zhang, C.D. James, J.I. Sznajder, L.Chin, D.A. Giljohann, J.A. Kessler, M.E. Peter, C.A. Mirkin, and A.H. Stegh, “miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma,” Genes and Development, vol. 29, no. 7, pp. 732-45, April 2015, https://doi.org/10.1101/gad.257394.
K. Yang, J. Wan, S. Zhang. B, Tian. Y. Zhang, and Z. Liu, “The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power,” Biomaterials, vol. 33, no. 7, pp. 2206-2214, December 2011, https://doi.org/10.1016/j.biomaterials.2011.11.064.
X. Ma, H. Tao, K. Yang, L. Feng, L. Cheng, X. Shi, Y. Li, L. Guo, and Z. Liu, “A functionalized graphene oxide-iron oxide nanocomposite for magnetically targeted drug delivery, photothermal therapy, and magnetic resonance imaging,” Nano Research, vol. 5, pp. 199–212, March 2012, https://doi.org/10.1007/s12274-012-0200-y.
K-P. Dieckmann, H. Simonsen-Richter, M. Kulejewski, P. Anheuser, H. Zecha, H. Isbarn, and U. Pichlmeier, “Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment,” BioMed Research International, vol. 2019, no. 5030349, pp. 1-22, May 2019, https://doi.org/10.1155/2019/5030349.
Y-E. Choi, J-W. Kwak, and J.W. Park, “Nanotechnology for Early Cancer Detection,” Sensors, vol. 10, pp. 428-455, January 2010, https://doi.org/10.3390/s100100428.
Y. Zhang, M. Li, X. Gao, Y. Chen, and T. Liu, “Nanotechnology in cancer diagnosis: progress, challenges and opportunities,” Journal of Hematology and Oncology, vol. 12, no. 137, pp. 1-13, December 2019, https://doi.org/10.1186/s13045-019-0833-3.
K.J. Arun, A.A. Navas and P.J.J. Francis, “Novel trends in the management of Alzheimerʼs disease by using nano based materials,” Madridge Journal of Nanotechnology and Nanoscience, vol. 3, no. 1, pp. 96-97, April 2018, https://doi.org/10.18689/mjnn-1000118.
S. Yu, Z. Chen, X. Zeng, X. Chen and Z. Gu, “Advances in nanomedicine for cancer starvation therapy,” Theranostics, vol. 9, no. 26, pp. 8026-8047, October 2019, https://doi.org/10.7150/thno.38261.
M. Swierczewska, H.S. Han, K. Kim, J.H. Park, and S. Lee, “Polysaccharide-based nanoparticles for theranostic nanomedicine,” Advanced Drug Delivery Reviews, vol. 99, part A, pp. 70-84, April 2016, https://doi.org/10.1016/j.addr.2015.11.015.
C. Wang, S. Ravi, U.S. Garapati, M. Das, M. Howell, J. Mallela, S. Alwarappan, S.S. Mohapatra, and S. Mohapatra, “Multifunctional chitosan magnetic-graphene (CMG) nanoparticles: a theranostic platform for tumor-targeted co-delivery of drugs, genes and MRI contrast agents,” Journal of Materials Chemistry B, vol. 1, pp. 4396-4405, June 2013, https://doi.org/10.1039/C3TB20452A.
S. Wang, Q. Zhang, X.F. Luo, J. Li, H. He, F. Yang, Y. Di, C. Jin, X.G. Jiang, S. Shen, and de L. Fu, “Magnetic graphene-based nanotheranostic agent for dual-modality mapping guided photothermal therapy in regional lymph nodal metastasis of pancreatic cancer,” Biomaterials, vol. 35, no. 35, pp. 9473-83, August 2014, https://doi.org/10.1016/j.biomaterials.2014.07.064.
L. Cui, C. Xiong. M, Zhou. S, Shi. D.S. Chow, and C. Li, “Integrin avß3-targeted CuS nanoparticles for PET/CT imaging and photothermal ablation therapy,” Bioconjugate Chemistry, vol, 29, no, 12, pp. 4062-4071, November 2018, https://doi.org/10.1021/acs.bioconjchem.8b00690.
X. Zhen, J. Zhang, J. Huang, C. Xie, Q. Miao, and K. Pu, “Macrotheranostic probe with disease-activated near-infrared fluorescence, photoacoustic, and photothermal signals for imaging-guided therapy,” Angewandte Chemie Internal Edition English, no. 57, no. 26, pp. 7804-7808, June 2018, https://doi.org/10.1002/anie.201803321.
S.R. y Cajal, M. Sesé, C. Capdevila, T. Aasen, De L. Mattos-Arruda, S.J. Diaz-Cano, J. Hernández-Losa, and Castellví. J. “Clinical implications of intratumor heterogeneity: challenges and opportunities,” Journal of Molecular Medicine, vol. 98, no. 2, pp. 161-177, February 2020, https://doi.org/10.1007/s00109-020-01874-2.
D.R. Welch, “Tumor heterogeneity – a ‘contemporary concept’ founded on historical insights and predictions,” Cancer Research, vol. 76, no. 1, pp. 4-6, January 2016, https://doi.org/10.1158/0008-5472.CAN-15-3024.
A. Skibinski and C. Kuperwasser, “The origin of breast tumor heterogeneity,” Oncogene, vol. 34, no. 5, pp. 5309-5316, October 2015, https://doi.org/10.1038/onc.2014.475.
S. Huang, “Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells,” Cancer Metastasis Review, vol. 32, no. 3-4, pp. 423–448, December 2013, https://doi.org/10.1007/s10555-013-9435-7.
T.J. McMillan and I.R. Hart, “Can cancer chemotherapy enhance the malignant behaviour of tumours?,” Cancer and Metastasis Reviews , vol.6, no. 4, pp. 503-520, February 1987, https://doi.org/10.1007/BF00047465.
F. Janku, “Tumor heterogeneity in the clinic: is it a real problem?”, Therapeutic Advances in Medical Oncology, vol. 6, no. 2, pp. 43-51, March 2014, https://doi.org/10.1177/1758834013517414.
R.D. Chow and S. Chen, “Cancer CRISPR screens in vivo,” Trends Cancer, vol. 4, no. 5, pp. 349-358, May 2018, https://doi.org/10.1016/j.trecan.2018.03.002.
A. Guernet and L. Grumolato, “CRISPR/Cas9 editing of the genome for cancer modeling,” Methods, vol. 121-122, pp. 130-137, May 2017, https://doi.org/10.1016/j.ymeth.2017.03.007.
C. Moses, B. Garcia-Bloj, A.R. Harvey, and P. Blancafort, “Hallmarks of cancer: The CRISPR generation,” European Journal of Cancer, vol. 93, pp. 10-18, April 2018, https://doi.org/10.1016/j.ejca.2018.01.002.
J.B. Miller, S. Zhang, P. Kos, H. Xiong, K. Zhou, S.S. Perelman, H. Zhu, and D.J. Siegwart, “Nonviral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA,” Angewandte Chemie International Edition, vol. 56, pp. 1059-1063, December 2016, https://doi.org/10.1002/anie.201610209.
B. Liu, A. Saber, and H.J. Haisma, “CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment,” Drug Discovery Today, vol. 24, no. 4, pp. 955-970, April 2019, https://doi.org/10.1016/j.drudis.2019.02.011.
X. Dai, X. Chen, Q. Fang, J. Li, and Z. Bai, “Inducible CRISPR genome-editing tool: classifications and future trends,” Critical Reviews in Biotechnology, vol. 38, no. 4, pp. 573-586, June 2018, https://doi.org/10.1080/07388551.2017.1378999.
L. Li, S. Hu, and X. Chen, “Nonviral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities,” Biomaterials, vol. 171, pp. 207-218, July 2018, https://doi.org/10.1016/j.biomaterials.2018.04.031.
Q. Liu, K. Zhao, C. Wang, Z. Zhang, C. Zheng, Y. Zhao, Y. Zheng, C. Liu, Y. An, L. Shi, C. Kang, and Y. Liu, “Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo,” Advanced Science, vol. 6, no. 1, pp. 1-12, October 2018, https://doi.org/10.1002/advs.201801423.
K. Schumann, S. Lin, E. Boyer, D.R. Simeonov, M. Subramaniam, R.E. Gate, G.E. Haliburton, C.J. Ye, J.A. Bluestone, J.A. Doudna, and A. Marson, “Generation of knock-in primary human T cells using Cas9 ribonucleoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 33, pp. 10437-10442, July 2015, https://doi.org/10.1073/pnas.1512503112.
M.L. Maeder, and C.A. Gersbach, “Genome-editing Technologies for Gene and Cell Therapy,” Molecular Therapy, vol. 24, no. 3, pp. 430-446, January 2016, https://doi.org/10.1038/mt.2016.10.
H. Gonzalez, C. Hagerling, and Z. Werb, “Roles of the immune system in cancer: from tumor initiation to metastatic progression,” Genes and Development, vol. 32, no. 19-20, pp. 1267-1284, October 2018, https://doi.org/10.1101/gad.314617.118.
B. Burkholder, R-Y. Huang, R. Burgess, S. Luo, V.S. Jones, W. Zhang, Z-Q. Lv, C-Y. Gao, B-L. Wang, Y-M. Zhang, and R-P. Huang, “Tumor-induced perturbations of cytokines and immune cell networks,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1845, no.2, pp. 182-201, April 2014, https://doi.org/10.1016/j.bbcan.2014.01.004.
M.A. ElTanbouly, W. Croteau, R.J. Noelle, and J.L. Lines, “VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity,” Seminars in Immunology, vol. 42, no. 101308, pp. 1-14, April 2019, https://doi.org/10.1016/j.smim.2019.101308.
A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, and P. Allavena, “Tumour-associated macrophages as treatment targets in oncology,” Nature Reviews Clinical Oncology, vol. 1, no. 7, pp. 399-416, July 2017, https://doi.org/10.1038/nrclinonc.2016.217.
A. Tanaka, and S. Sakaguchi, “Regulatory T cells in cancer immunotherapy,” Cell Research, vol. 27, no.1, pp. 109-118, January 2017, https://doi.org/10.1038/cr.2016.151.
M.A. Smolle, and M. Pichler, “Inflammation, phagocytosis and cancer: another step in the CD47 act,” Journal of Thoracic Disorders, vol. 9, no. 8, pp. 2279-2282, August 2017, https://doi.org/10.21037/jtd.2017.07.38.
M.S. Goldberg, “Improving cancer immunotherapy through nanotechnology,” Nature Reviews Cancer, vol. 19, pp. 587-602, October 2019, https://doi.org/10.1038/s41568-019-0186-9.
M. Kalos, B.L. Levine, D.L, Porter, S. Katz, S.A. Grupp, A. Bagg, and C.H. June, “T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia,” Science Translational Medicine, vol. 3, no. 95, pp. 95-73, August 2011, https://doi.org/10.1126/scitranslmed.3002842.
C. Graham, R. Hewitson, A. Pagliuca, and B. Reuben “Cancer immunotherapy with CAR-T cells – behold the future,” Clinical Medicine, vol. 18, no. 4, pp. 324-328, August 2018, https://doi.org/10.7861/clinmedicine.18-4-324.
S.S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F.L. Locke, K.V. Komanduri, Y. Lin, N. Jain, N. Daver, J. Westin, A.M. Gulbis, M.E. Loghin, J.F. de Groot, S. Adkins, S.E. Davis, K. Rezvani, P. Hwu. and E.J. Shpall, “Chimeric antigen receptor T-cell therapy - assessment and management of toxicities,” Nature Reviews Clinical Oncology, vol, 15, no. 1, pp. 47-62, January 2018, https://doi.org/10.1038/nrclinonc.2017.148.
M.L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S.S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D.C. Bouhassira, M.E. Arcila, M. Gonen, G.J. Roboz, P. Maslak, D. Douer, M.G. Frattini, S. Giralt, M. Sadelain, and R. Brentjens, “Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia,” Science Translational Medicine, vol. 6, no. 224, pp. 224-25, February 2014, https://doi.org/10.1126/scitranslmed.3008226.
C.H. June and M. Sadelain, “Chimeric Antigen Receptor Therapy,” The New England Journal of Medicine, vol. 379, pp. 64-73, July 2018, https://doi.org/10.1056/NEJMra1706169.
D. Akhavan, D. Alizadeh, D. Wang, M.R. Weist, J. Shepphird, and C.E. Brown, “CAR T cells for brain tumors: Lessons learned and road ahead,” Immunological Reviews, vol. 290, no. 1, pp. 60-84, July 2019, https://doi.org/10.1111/imr.12773.
S.Y. Gun, S.W.L. Lee, J.L. Sieow, and S.C. Wong, “Targeting immune cells for cancer therapy,” Redox Biology, vol. 25, no. 101174, pp. 1-16, March 2019, https://doi.org/10.1016/j.redox.2019.101174.
J. Seidel, A. Otsuka, and K. Kabashima, “Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations,” Frontiers in Oncology, vol. 8, no. 86, pp. 1-14, March 2018, https://doi.org/10.3389/fonc.2018.00086.
E. Hui, “Immune checkpoint inhibitors,” Journal of Cell Biology, vol. 218, no. 3, pp. 740–741, February 2019, https://doi.org/10.1083/jcb.201810035.
A. Rotte, J.Y. Jin, and V. Lemaire, “Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy,” Annals of Oncology, vol. 29, no. 1, pp. 71-83, January 2018, https://doi.org/10.1093/annonc/mdx686.
Y. Han, D. Liu, and L. Li, “PD-1/PD-L1 pathway: current researches in cancer,” American Journal of Cancer Research, vol. 10, no. 3, pp. 727-742, March 2020.
J.J. Havel, D. Chowell, and T.A. Chan, “The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy,” Nature Reviews Cancer, vol. 19, no. 3, pp. 133-150, March 2019, https://doi.org/10.1038/s41568-019-0116-x.
C. Robert, “A decade of immune-checkpoint inhibitors in cancer therapy,” Nature Communications, vol. 11, no. 3801, pp. 1-3, July 2020, https://doi.org/rg/10.1038/s41467-020-17670-y.
G.K. Pennock, and L.Q.M. Chow, “The evolving role of immune checkpoint inhibitors in cancer treatment,” The Oncologist, vol. 20, no. 7, pp. 812-822, July 2015, https://doi.org/10.1634/theoncologist.2014-0422.
A. Haslam, and V. Prasad, “Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs,” JAMA Network Open, vol. 2, no. 5, pp. 1-9, May 2019, https://doi.org/10.1001/jamanetworkopen.2019.2535.
D. Schadendorf, F.S. Hodi, C. Robert, J.S. Weber, K. Margolin, O. Hamid, D. Patt, T.T. Chen, D.M. Berman, and J.D. Wolchok, “Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma,” Journal of Clinical Oncology, vol. 33, no. 17, pp. 1889-94, June 2015, https://doi.org/10.1200/JCO.2014.56.2736.
C. Robert, R. Ribas, O. Hamid, A. Daud, J.D. Wolchok, A.M. Joshua, W-J. Hwu, J.S. Weber, T.C. Gangadhar, R.W. Joseph, R. Dronca, A. Patnaik, H. Zarour, R. Kefford, P. Hersey, J. Zhang, J. Anderson, S.J. Diede, S. Ebbinghaus. and F.S. Hodi, “Durable complete response after discontinuation of pembrolizumab in patients With metastatic melanoma,” Journal of Clinical Oncology, vol. 36, no. 17, pp. 1668-1674, June 2018, https://doi.org/10.1200/JCO.2017.75.6270.
S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, J.A. Sosman, M.B. Atkins, P.D. Leming, D.R.Spigel, S.J. Antonia, A. Drilon, J.D. Wolchok, R.D. Carvajal, M.B. McHenry, F. Hosein, C.T. Harbison, J.F. Gross, and M. Sznol, “Five-Year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab,” JAMA Oncology, vol. 5, no. 10, pp. 1411-1420, July 2019, https://doi.org/10.1001/jamaoncol.2019.2187.
M.S. Goldberg, “Immunoengineering: how nanotechnology can enhance cancer immunotherapy,” Cell, vol. 161, pp. 201-204, April 2015, https://doi.org/10.1016/j.cell.2015.03.037.
Y. Min, K.C. Roche, and S. Tian, “Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy,” Nature Nanotechnology, vol. 12, no. 9, 877-882, June 2017, https://doi.org/10.1038/nnano.2017.113.
F.F. Gellrich, M. Schmitz, S. Beissert, and F. Meier, “Anti-PD-1 and novel combinations in the treatment of melanoma – an update,” Journal of Clinical Medicine, vol. 9, no. 1, p. 223, January 2020, https://doi.org/10.3390/jcm9010223.
I. Morales-Orue, R. Chicas-Sett, and P.C. Lara, “Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies,” Reports of Practical Oncology and Radiotherapy, vol. 24, no. 1, pp. 86-91, January 2019, https://doi.org/10.1016/j.rpor.2018.11.001.
G. Köhler and C. Milstein “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, vol. 256, no. 5517, pp. 495-497, September 1975, https://doi.org/10.13140/RG.2.2.33835.90401.
J. Lohmueller, and O.J. Finn, “Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines,” Pharmacology and Therapeutics, vol. 178, pp. 31-47, March 2017, https://doi.org/10.1016/j.pharmthera.2017.03.008.
A.M. Scott, J.D. Wolchok, and L.J. Old, “Antibody therapy of cancer,” Nature Reviews Cancer, vol. 12, no. 4, pp. 278–287, March 2012, https://doi.org/10.1038/nrc3236.
P.A. Ascierto, and F.M. Marincola, “2015: The year of anti-PD-1/PD-L1s against melanoma and beyond,” EBioMedicine, vol. 2, no. 2, pp. 92-93, February 2015, https://doi.org/10.1016/j.ebiom.2015.01.011.
D. Zahavi, and L. Weiner, “Monoclonal antibodies in cancer therapy,” Antibodies, vol. 9, no. 3, p. 34, July 2020, https://doi.org/10.3390/antib9030034.
M.S. Castelli, P. McGonigle, and P.J. Hornby “The pharmacology and therapeutic applications of monoclonal antibodies,” Pharmacology Research and Perspectives, vol. 7, no. 6, pp. 1-11, December 2019, https://doi.org/10.1002/prp2.535.
V. Janelle, C. Rulleau, S.D. Testa, C. Carli, and J-S. Delisle, “T-cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies,” Frontiers in Immunology, vol. 11, no. 276, pp. 1-15, February 2020, https://doi.org/10.3389/fimmu.2020.00276.
A. Karlitepe, O. Ozalp, and C.B. Avci, “New approaches for cancer immunotherapy,” Tumor Biology, vol. 36, no. 6, pp. 4075-4078, May 2015, https://doi.org/10.1007/s13277-015-3491-2.
M. Sambi, L.Bagheri, and M.R. Szewczuk, “Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates,” Journal of Oncology, vol. 2019, no. 508794, pp. 1-12, February 2019, https://doi.org/10.1155/2019/4508794.
I. Melero, G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, N. Thatcher, J. Wagstaff, C. Zielinski, I. Faulkner, and H. Mellstedt, “Therapeutic vaccines for cancer: an overview of clinical trials,” Nature Reviews Clinical Oncology, vol. 11, no. 9, pp. 509-524, September 2014, https://doi.org/10.1038/nrclinonc.2014.111.
This work is licensed under a Creative Commons Attribution 4.0 International License.